コンテンツへスキップ
Merck
  • The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus.

The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus.

European journal of drug metabolism and pharmacokinetics (2012-11-28)
Aida Kulo, Sarah Hendrickx, Jan de Hoon, Nedzad Mulabegovic, Kristel van Calsteren, Rene Verbesselt, Karel Allegaert
要旨

Compared to female volunteers or postpartum, ketorolac clearance is higher at delivery. To explore the alterations that explain this higher clearance, urinary ketorolac metabolites collected at delivery (n = 40) were compared to female volunteers (unpaired, n = 8) or postpartum (paired, n = 8) following intravenous administration of 30 mg ketorolac tromethamine. A mean 38 (SD 9) % of the ketorolac dose was retrieved in 8-h urine collections. This was based on mean portions of 56 (20), 10 (14) and 33 (12) % for free ketorolac, ketorolac-glucuronide and p-hydroxy-ketorolac, respectively. The mean ketorolac-glucuronide portion at delivery (5 %) was lower compared to female volunteers (21 %) or postpartum (21 %) (p = 0.003 and p = 0.002, respectively). Similarly, there was a difference in mean portion of free urinary ketorolac at delivery when compared to healthy female volunteers (60-45 %, p = 0.046). Using paired statistics, the mean portion of total urinary ketorolac was lower (62-73 %, p = 0.015) while the portion retrieved as p-hydroxy-ketorolac was significantly higher at delivery compared to postpartum (38-28 %, p = 0.031). The differences in urine metabolites suggest that the increased ketorolac clearance at delivery is in part explained by increased metabolic clearance to p-hydroxy-ketorolac, reflecting increased oxidation activity.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ケトロラック トリス塩, ≥99%, crystalline
Supelco
ケトロラック トリス塩, Pharmaceutical Secondary Standard; Certified Reference Material
ケトロラック トリス塩, European Pharmacopoeia (EP) Reference Standard
ケトロラック トリス塩, European Pharmacopoeia (EP) Reference Standard